BACKGROUND: Demand for devices that allow the self-assessment of blood pressure continues to rise. Few self-assessment devices, however, have been validated against recognised protocols. The aim of this study was to validate the Omron MX3 Plus (model HEM-742-E) oscillometric blood pressure measuring device in accordance with the international protocol of the European Society of Hypertension. This automated device is currently available to the public in the UK through high-street chemists and other outlets. DESIGN: The European Society of Hypertension's international protocol for validation of blood pressure measuring devices in adults divides validation into two phases. The first phase is performed on 15 individuals, five in each of three specific blood pressure categories. If the device passes the first phase then a further 18 patients are recruited, making a total of 33 individuals on which the final validation is based. All subjects are aged 30 years or above. METHODS: The automated device was connected in parallel to two reference mercury sphygmomanometers. Nine sequential same-arm measurements were taken from each subject by two trained observers, alternating between the mercury sphygmomanometers and the test device. RESULTS: The Omron MX3 Plus passed both phases of the ESH validation process. The mean (standard deviation) of the difference between the observer and the device measurements was -1.15 (5.7) mmHg for systolic and -1.61 (4.7) mmHg for diastolic pressures, respectively. CONCLUSIONS: The Omron MX3 Plus can be recommended for home and professional use in an adult population.
BACKGROUND: Demand for devices that allow the self-assessment of blood pressure continues to rise. Few self-assessment devices, however, have been validated against recognised protocols. The aim of this study was to validate the Omron MX3 Plus (model HEM-742-E) oscillometric blood pressure measuring device in accordance with the international protocol of the European Society of Hypertension. This automated device is currently available to the public in the UK through high-street chemists and other outlets. DESIGN: The European Society of Hypertension's international protocol for validation of blood pressure measuring devices in adults divides validation into two phases. The first phase is performed on 15 individuals, five in each of three specific blood pressure categories. If the device passes the first phase then a further 18 patients are recruited, making a total of 33 individuals on which the final validation is based. All subjects are aged 30 years or above. METHODS: The automated device was connected in parallel to two reference mercury sphygmomanometers. Nine sequential same-arm measurements were taken from each subject by two trained observers, alternating between the mercury sphygmomanometers and the test device. RESULTS: The Omron MX3 Plus passed both phases of the ESH validation process. The mean (standard deviation) of the difference between the observer and the device measurements was -1.15 (5.7) mmHg for systolic and -1.61 (4.7) mmHg for diastolic pressures, respectively. CONCLUSIONS: The Omron MX3 Plus can be recommended for home and professional use in an adult population.
Authors: Robert B Schonberger; Adambeke Nwozuzu; Jill Zafar; Eric Chen; Simon Kigwana; Miriam M Monteiro; Jean Charchaflieh; Sophisa Sophanphattana; Feng Dai; Matthew M Burg Journal: J Am Soc Hypertens Date: 2018-02-06
Authors: Suliman Mansi; Stephan Milosavljevic; Steve Tumilty; Paul Hendrick; Chris Higgs; David G Baxter Journal: BMC Public Health Date: 2015-04-22 Impact factor: 3.295